NBIX

Business Context and Reporting Period

Company: Neurocrine Biosciences, Inc. (NBIX)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2026
Business Overview: Neurocrine is a neuroscience-focused biopharmaceutical company developing treatments for neurological, psychiatric, endocrine, and immunological disorders. Key commercial products include INGREZZA (valbenazine) for tardive dyskinesia and Huntington's disease chorea, and CRENESSITY (crinecerfont) for classic congenital adrenal hyperplasia (CAH).

Key Financial Metrics

Profitability Margins (Q1 2026):
- Gross Margin: 98.3% (Net Product Sales / Cost of Revenues)
- Operating Margin: 23.7%
- Net Profit Margin: 24.3%

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 42.2% year-over-year, driven by a 20.5% increase in INGREZZA sales ($656.9M vs. $545.2M) and a 957% increase in CRENESSITY sales ($153.3M vs. $14.5M) following its December 2024 launch.
• Operating Expenses: Total operating expenses rose to $621.1M from $549.0M. R&D expenses increased to $296.2M due to late-stage program progression (osavampator, direclidine) and a $22.5M milestone payment to Nxera. SG&A increased to $318.5M due to commercial team expansion.
• Unusual Items: The company recognized a pre-tax gain of $28.6M from the sale of Neurocrine Group Limited in January 2026. Additionally, unrealized gains on equity investments contributed $25.3M to other income, compared to a $30.6M loss in the prior year.
• Liquidity: Cash and cash equivalents decreased from $713.0M at year-end 2025 to $266.5M at March 31, 2026, primarily due to net investing outflows of $506.2M (purchases of debt securities) and financing outflows of $86.1M (share repurchases).

Guidance, Outlook, and Risks

Strategic Transactions:

• Soleno Acquisition: On April 5, 2026, Neurocrine entered into an agreement to acquire Soleno Therapeutics, Inc. for approximately $2.9 billion in cash ($53.00 per share). The HSR waiting period expired on April 27, 2026. The transaction is expected to close in Q2 2026, funded by cash on hand and available investments.
• Share Repurchases: Under the 2025 Repurchase Program ($500M authorized), the company repurchased 0.4 million shares for $56.0M in Q1 2026. Approximately $276.3M remains available under this program.

Outlook & Commentary:

• Management expects existing capital resources and anticipated sales to satisfy funding requirements for at least the next 12 months, though the Soleno acquisition will significantly reduce cash balances.
• Pipeline highlights include the initiation of Phase 2 studies for NBI-1117570 (schizophrenia) and continued Phase 3 development of osavampator (MDD).

Risks & Contingencies:

• Regulatory & Legal: Ongoing DOJ investigation regarding INGREZZA sales and marketing; FDA warning letter regarding promotional claims received in September 2025. Patent litigation with Zydus regarding generic INGREZZA SPRINKLE.
• Commercial: Dependence on a concentrated customer base (four customers represent >90% of gross product sales). Risks related to the commercial success of CRENESSITY and potential pricing pressures from the Inflation Reduction Act (IRA).
• Operational: Reliance on third-party manufacturers; integration risks associated with the Soleno acquisition.

Investor Verification Checklist

• Soleno Acquisition Status: Verify the final closing date and any changes to the $2.9B valuation or financing terms.
• CRENESSITY Commercialization: Monitor Q2 2026 sales data to confirm the sustainability of the growth trajectory post-launch.
• DOJ Investigation: Track updates on the Department of Justice inquiry into INGREZZA marketing practices and potential settlement terms.
• Liquidity Post-Acquisition: Assess the impact of the Soleno cash outlay on the company's ability to fund R&D and future capital needs without additional financing.
• Patent Litigation: Review the status of the Zydus ANDA litigation and potential impact on INGREZZA exclusivity.